May 20th 2024
Jose Lutzky, MD, discussed the promise of tumor infiltrating lymphocyte therapy for difficult-to-treat advanced melanoma.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Increased Risk of Skin Cancer Seen in Military Veterans
May 19th 2022For military veterans, future research should be accompanied by systematic efforts to improve skin cancer prevention, treatment, and outcomes among military service members and veterans, according to Carolyn J. Heckman, PhD.
Read More
Spartalizumab With Dabrafenib and Trametinib Shows Modest Efficacy in BRAF V600+ Metastatic Melanoma
May 5th 2022The phase 3 COMBI-i trial demonstrated that spartalizumab plus dabrafenib and trametinib has modest efficacy in BRAF V600-positive metastatic melanoma, but no progression-free survival benefit when compared with dabrafenib and trametinib alone.
Read More
ADAPT-IT Raises Question About 4-Dose Schedule of Nivo/Ipi in Patients With Metastatic Melanoma
April 8th 2022Efficacy and toxicity of standard four dose nivolumab and ipilimumab induction therapy in melanoma to be likely driven by the first 2 doses as demonstrated in the Adaptively Dosed ImmunoTherapy Trial.
Read More
PIVOT IO-001 Enrollment Stops After Trial Failure, But Analyses Continue
March 15th 2022In PIVOT IO-001, patients with metastatic melanoma are no longer being enrolled and treatment arms have been unblinded after the combination of bempegaldesleukin and nivolumab did not meet its coprimary end points.
Read More
FDA Approves Tebentafusp-tebn in Adult HLA-A*02:01-Positive Unresectable/Metastatic Uveal Melanoma
January 26th 2022Tebentafusp-tebn has been granted FDA approval to treat HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma based on positive results from a phase 3 study.
Read More
Doctors Debate: Should Stage III Melanoma Be Treated in the Adjuvant or Neoadjuvant Setting?
January 20th 2022During a recent medical meeting, Michael Lowe, MD, MA, FACS, FSSO, and Ragini Kudchadkar, MD, debated adjuvant therapy versus neoadjuvant for the treatment of resectable stage III melanoma.
Read More
Nivolumab/Relatlimab Combo Improves PFS in Advanced Melanoma
January 6th 2022Efficacy was seen with blocking LAG-3 in combination with PD-1 as a therapeutic strategy for patients with melanoma. Additionally, this research establishes LAG-3 as the third immune checkpoint pathway to have proven clinical benefit in this patient population.
Read More
Darovasertib/Crizotinib Shows Early Efficacy in Metastatic Uveal Melanoma
December 10th 2021Darovasertib and crizotinib demonstrated promising efficacy and tolerable safety in patients with metastatic uveal melanoma, according to preliminary results of a phase 1/2 trial announced in a press release from IDEAYA Biosciences.
Read More
Second-Line Cemiplimab Improves Survival and Quality of Life in Cervical Squamous Cell Carcinoma
October 5th 2021Results from the EMPOWER-Cervical 1/ GOG-3016/ENGOT-cx9 trial led the FDA to grant priority review to cemiplimab as treatment of patients with recurrent or metastatic cervical cancer whose disease progressed on or after chemotherapy.
Read More
Risk Information Can Influence Clinical Decision-Making in Melanoma
July 27th 2021Cutaneous melanoma is disproportionately lethal among skin cancers, and as incidence rates of cutaneous melanoma continue to rise in the United States, so does the importance of managing melanoma cases in alignment with personalized prognoses.
Read More